Literature DB >> 21931106

Glucose tolerance status and risk of dementia in the community: the Hisayama study.

T Ohara1, Y Doi, T Ninomiya, Y Hirakawa, J Hata, T Iwaki, S Kanba, Y Kiyohara.   

Abstract

OBJECTIVE: We investigated the association between glucose tolerance status defined by a 75-g oral glucose tolerance test (OGTT) and the development of dementia.
METHODS: A total of 1,017 community-dwelling dementia-free subjects aged ≥60 years who underwent the OGTT were followed up for 15 years. Outcome measure was clinically diagnosed dementia.
RESULTS: The age- and sex-adjusted incidence of all-cause dementia, Alzheimer disease (AD), and vascular dementia (VaD) were significantly higher in subjects with diabetes than in those with normal glucose tolerance. These associations remained robust even after adjustment for confounding factors for all-cause dementia and AD, but not for VaD (all-cause dementia: adjusted hazard ratio [HR] = 1.74, 95% confidence interval [CI] = 1.19 to 2.53, p = 0.004; AD: adjusted HR = 2.05, 95% CI = 1.18 to 3.57, p = 0.01; VaD: adjusted HR = 1.82, 95% CI = 0.89 to 3.71, p = 0.09). Moreover, the risks of developing all-cause dementia, AD, and VaD significantly increased with elevated 2-hour postload glucose (PG) levels even after adjustment for covariates, but no such associations were observed for fasting plasma glucose (FPG) levels: compared with those with 2-hour PG levels of <6.7 mmol/L, the multivariable-adjusted HRs of all-cause dementia and AD significantly increased in subjects with 2-hour PG levels of 7.8 to 11.0 mmol/L or over, and the risk of VaD was significantly higher in subjects with levels of ≥11.1 mmol/L.
CONCLUSIONS: Our findings suggest that diabetes is a significant risk factor for all-cause dementia, AD, and probably VaD. Moreover, 2-hour PG levels, but not FPG levels, are closely associated with increased risk of all-cause dementia, AD, and VaD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21931106     DOI: 10.1212/WNL.0b013e31822f0435

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  122 in total

Review 1.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

Review 2.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

3.  Adenovirus-Mediated Transduction of Insulin-Like Growth Factor 1 Protects Hippocampal Neurons from the Toxicity of Aβ Oligomers and Prevents Memory Loss in an Alzheimer Mouse Model.

Authors:  Maria Clara Selles; Juliana T S Fortuna; Maria F Zappa-Villar; Yasmin P R de Faria; Amanda S Souza; Claudia K Suemoto; Renata E P Leite; Roberta D Rodriguez; Lea T Grinberg; Paula C Reggiani; Sergio T Ferreira
Journal:  Mol Neurobiol       Date:  2019-11-23       Impact factor: 5.590

Review 4.  Diabetes and cognition.

Authors:  Elizabeth Rose Mayeda; Rachel A Whitmer; Kristine Yaffe
Journal:  Clin Geriatr Med       Date:  2014-11-15       Impact factor: 3.076

5.  Poster Viewing Sessions PB01-B01 to PB03-V09.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2019-07       Impact factor: 6.200

6.  Cognitive deficits in non-demented diabetic elderly appear independent of brain amyloidosis.

Authors:  Gloria C Chiang; Eileen Chang; Sneha Pandya; Amy Kuceyeski; James Hu; Richard Isaacson; Christine Ganzer; Aaron Schulman; Vivian Sobel; Shankar Vallabhajosula; Lisa Ravdin
Journal:  J Neurol Sci       Date:  2016-11-17       Impact factor: 3.181

Review 7.  Emerging links between type 2 diabetes and Alzheimer's disease.

Authors:  Gumpeny R Sridhar; Gumpeny Lakshmi; Gumpeny Nagamani
Journal:  World J Diabetes       Date:  2015-06-10

8.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

9.  Diabetes, Hemoglobin A1C, and Regional Alzheimer Disease and Infarct Pathology.

Authors:  Jeremy J Pruzin; Julie A Schneider; Ana W Capuano; Sue E Leurgans; Lisa L Barnes; Rexford S Ahima; Steven E Arnold; David A Bennett; Zoe Arvanitakis
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Jan-Mar       Impact factor: 2.703

Review 10.  Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums.

Authors:  Steven E Arnold; Zoe Arvanitakis; Shannon L Macauley-Rambach; Aaron M Koenig; Hoau-Yan Wang; Rexford S Ahima; Suzanne Craft; Sam Gandy; Christoph Buettner; Luke E Stoeckel; David M Holtzman; David M Nathan
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.